Pharmacokinetic Evaluation of an Intensified and Decreasing Dosing Regimen of Mycophenolate Sodium in Combination With Tacrolimus Post Kidney Transplant: The Myfortic Study

Pharmacokinetic Evaluation of an Intensified and Decreasing Dosing Regimen of Mycophenolate Sodium in Combination With Tacrolimus During the First 3 Months Post Kidney Transplant (the myFORTic Study)

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00941824

Enrollment

Registered

2009-07-20

Start date

2009-02-28

Completion date

2010-03-31

Last updated

2010-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Transplantation

Keywords

pharmacokinetic, mycophénolate acid, kidney transplantation

Brief summary

Mycophenolate acid (MPA) has been developed and approved in combination with cyclosporine and has been used in kidney transplantation for more than a decade. At present, combination of tacrolimus and mycophenolate acid tends to be considered as the standard of care for maintenance immunosuppression in kidney transplantation. Mainly due to a different effect on the entero-hepatic recycling pathway, cyclosporine and tacrolimus differently interfere with MPA clearance. When used with tacrolimus, MPA dosage has thus to be adjusted and cannot be extrapolated from what is recommended for a cyclosporine-based treatment. However, there is currently no clear guideline for MPA dosing when this drug is used in combination with tacrolimus. This is potentially detrimental for patients since under-or overexposure of MPA has been clinically linked to the outcome of transplantation. The purpose of this study is to pharmacologically validate an original MPA dosing regimen in combination with tacrolimus within the three months post-kidney transplant. This regimen consists in an intensified dosing of mycophenolate sodium during the earliest period of transplantation in order to rapidly reach the appropriate MPA blood exposure followed by a gradual decrease in dose in order to prevent MPA overexposure.

Interventions

DRUGmycophénolate acid

* Day 0 to Day 7, 720 mg twice daily * Day 8 to Day 30, 540 mg twice daily * Day 30 to Day 90, 360 mg twice daily

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* \>18 years * Renal transplant from a dead or alive donor. * Patients treated by initial quadritherapy with basiliximab, tacrolimus, steroid et mycophenolate sodic * ΒHCG pregnancy test negative at the initiation of Myfortic ® * Effective contraception during treatment and up to 6 weeks after treatment with Myfortic ®

Exclusion criteria

* Patient at high risk of rejection of a transplant * IMC \> ou = 30 * Platelets \< 75000 / mm3 and/or neutrophils \< 1500 / mm3 and/or leukocytes \< 2500/ mm3 and/or hemoglobin \< 6 g/dL. * Patient requiring a anti-CMV prophylaxis by valganciclovir. * Pregnancy or breast feeding.

Design outcomes

Primary

Measure	Time frame
Area under the curve (AUC0 - 12 hours) of the MPA and its métabolites MPAG and Ac-MPAG	at Day 2, Day 7, Day 15, Month 1, Month 3

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026